Our results reveal that endogenous IL-6 and downstream IL-6 effectors that support cancer stemness21 are associated with poor clinical responses to ICI, and that combined IL-6 blockade and ICI in mice induces CD8+ T-cell expansion while suppressing CD4+ regulatory T cell (Treg) infiltration to reprogram the TIME and improve overall survival. This evidence concerns the gene IL6 and cancer.